Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
ACHV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.84 - $5.31
Previous CloseN/A
Volume131.37K
Average Volume (3M)1.32M
Market Cap
$153.83M
Enterprise Value$32.95M
Total Cash (Recent Filing)$55.40M
Total Debt (Recent Filing)$9.96M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 06, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding51,104,970
10 Day Avg. Volume769,186
30 Day Avg. Volume1,316,883
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.21
Enterprise Value/Revenue144.52
Enterprise Value/Gross Profit-10.98K
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$14.60Price Target Upside385.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe Affordable Care Act and other federal laws and rules require most health insurance plans in the U.S. to cover some level of tobacco cessation treatments, which bodes well for the uptake of cytisinicline.
Regulatory ApprovalThe FDA has accepted its NDA for its smoking cessation treatment, cytisinicline, with a PDUFA date set for 6/20/26.
Strategic PartnershipsA strategic partnership with Omnicom to co-develop and execute a fully integrated, AI-enabled US launch strategy for cytisinicline has been announced, pending FDA approval.
Bears Say
Financial PositionACHV's current enterprise value does not reflect the strength of the data supporting the NDA or the size of the addressable market, where peak cytisinicline sales could reach multiples of the current valuation.
Market PerceptionACHV shares do not currently reflect the full commercial potential of cytisinicline, especially given the limitations of existing therapies and the growing public health impact of smoking and vaping.
Valuation ConcernsThe market cap of approximately $144 million does not reflect the large market opportunity for a new smoking cessation product.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $1.84 and its highest was $5.31 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Achieve Life Sciences Inc’s market cap is $153.83M.
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Nov 06, 2025 which is in 37 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Aug 07, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.366 by -$0.004.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -0.24.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 51,104,970 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.366. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
Achieve Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.60 (385.05% Upside)
$14.60 (385.05% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.20%
12-Months-Change
Fundamentals
Return on Equity
-120.11%
Trailing 12-Months
Asset Growth
-9.04%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. (ACHV) is a clinical-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction. Operating primarily within the biopharmaceutical sector, the company's core focus is on addressing the global smoking health crisis by providing an alternative to existing smoking cessation therapies.
ACHV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in regulatory submissions, strategic partnerships, and capital acquisition, indicating strong progress toward commercialization. However, the extended timeline to launch and potential pricing challenges present notable hurdles.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$14.60
▲(385.05% Upside)
Technical Analysis
Ownership Overview
1.19% Insiders
7.94% Mutual Funds
32.88% Other Institutional Investors
51.85% Public Companies and Individual Investors